Angiotensin-converting enzyme inhibitors derived from lactic acid bacteria

Abstract

To provide an ACE inhibitor derived from Lactococcus lactic acid bacteria with high safety.SOLUTION: An angiotensin-converting enzyme inhibitor contains at least one selected from a viable cell body, a dead cell and extract of Lactococcus lactis N7 strain (accession number: FERM P-18217). There are also provided a skin aging inhibitory composition and a wrinkle improving composition each containing the angiotensin-converting enzyme inhibitor as an active ingredient, and a method for increasing ACE inhibitory activity by using the angiotensin-converting enzyme inhibitor.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an angiotensin-converting enzyme inhibitor, a skin aging inhibition composition and a wrinkle improving composition containing said inhibitor, and a method for increasing angiotensin-converting enzyme inhibitory activity. [Background technology]

[0002] Angiotensin-converting enzyme (hereinafter referred to as "ACE") is an enzyme that exists mainly in pulmonary vascular endothelial cells, and acts on angiotensin I to release a dipeptide from its terminal, generating angiotensin II, which has a strong blood pressure increasing effect. ACE also has the effect of decomposing and inactivating bradykinin, which has a blood pressure lowering effect. In this way, ACE produces a hypertensive peptide (angiotensin II) while at the same time decomposing and inactivating a hypotensive peptide (bradykinin), which results in an increase in blood pressure. In other words, by inhibiting ACE, it is possible to suppress an increase in blood pressure, and therefore various research and development efforts are being conducted on ACE inhibitors as effective oral antihypertensive drugs. On the other hand, it has been reported recently that photoaging of the skin can be suppressed by inhibiting ACE expressed in the skin with an ACE inhibitor (Non-Patent Document 1), and a wrinkle-improving composition utilizing this has been proposed (e.g., Patent Document 1, etc.).

[0003] Many natural and synthetic substances, including snake venom peptides, have been reported as ACE inhibitors, and synthetic substances such as captopril (N-[(S)-3-mercapto-2-methylpropionyl]-L-proline) have already been put to practical use as oral antihypertensive drugs. However, pharmaceuticals that use synthetic substances as active ingredients have safety issues such as side effects, so ACE inhibitors derived from natural products are being researched in various fields in hopes of developing a safer antihypertensive drug. Certain types of lactic acid bacteria are known as probiotics (microorganisms that contribute to maintaining the health of the host when taken orally in appropriate amounts), and various benefits have been reported. Meanwhile, there are also reports of topical preparations using lactic acid bacteria components (Non-Patent Document 2). Consumers have a good image of lactic acid bacteria, and in addition, there is a demand for the development of safe ACE inhibitors derived from lactic acid bacteria, in order to develop new cosmetic materials that are inexpensive and can be prepared by being derived from microorganisms rather than synthetic substances. It has been reported that certain types of lactic acid bacteria produce peptides that exhibit ACE inhibitory activity during milk fermentation (e.g., Patent Document 2, etc.). The production of these functional peptides is affected by the protein degradation ability of the strain, and lactic acid bacteria that produce effective peptide species and amounts are limited, and those with low said activity have been excluded from screening for lactic acid bacteria that exhibit ACE inhibitory activity. Lactic acid bacteria are currently divided into 44 genera, some of which are less safe. Of these, new proposals are needed for ACE inhibitors derived from Lactococcus lactic acid bacteria, which have been confirmed to be highly safe, and which are unrelated to the strain's protein degradation ability. By screening from those that are unrelated to the strain's protein degradation ability, the number of strains that can be screened may increase, making it easier to find effective strains. In addition, protein degradation ability is often dependent on the activity of the strain's proteolytic enzymes, and the only way to increase the enzyme activity is to use methods such as genetic modification. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2011-148734 A [Patent Document 2] JP 2008-133251 A [Non-patent literature]

[0005] [Non-Patent Document 1] Matsuura-Hachiya et al. 2013. Biochem. Biophys. Res. Commun. [Non-Patent Document 2] Khmaladze et al. 2019. Exp. Dermatol. [Non-Patent Document 3] Kimoto-Nira et al. 2019. Lett. Appl. Micobiol. Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention aims to provide an ACE inhibitor derived from Lactococcus lactic acid bacteria that is highly safe and is widely used in probiotics, and to provide a skin aging inhibition composition and wrinkle improvement composition that use said inhibitor, as well as a simple method for increasing ACE inhibitory activity. [Means for solving the problem]

[0007] As a result of extensive research into solving the above problems, the present inventors have discovered that certain lactic acid bacteria belonging to the genus Lactococcus themselves have high ACE inhibitory activity, thereby solving the above problems.

[0008] Specifically, the present invention relates to the following items. 1. An angiotensin-converting enzyme inhibitor comprising one or more substances selected from live cells, killed cells, and extracts of Lactococcus lactis N7 strain (accession number: FERM P-18217). 2. A composition for inhibiting skin aging, comprising as an active ingredient the angiotensin-converting enzyme inhibitor described in 1. 3. A wrinkle-improving composition comprising the angiotensin-converting enzyme inhibitor described in 1. as an active ingredient. 4. A method for increasing angiotensin-converting enzyme inhibitory activity, comprising culturing Lactococcus lactis N7 strain (accession number: FERM P-18217) in the presence of a specific carbon source and / or heat treating it. Effect of the Invention

[0009] The lactic acid bacteria N7 strain of the present invention, which belongs to Lactococcus, has a high ACE inhibitory activity and is therefore highly safe. The lactic acid bacteria N7 strain of the present invention can be used as a composition for inhibiting skin aging and for improving wrinkles. [Brief description of the drawings]

[0010] [Figure 1] 1 is a graph showing the test results of "Test to confirm ACE inhibitory activity of lactic acid bacteria N7 and H61 strains" in Example 1. [Diagram 2] 1 shows microscopic images stained with SA-β-Gal in “Examination of the effect of lactic acid bacteria N7 strain on the cell proliferation ability of senescence-induced normal human dermal fibroblast cells” in Example 5. The left side shows an image of a non-senescence-induced cell, and the right side shows an image of a senescence-induced cell. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The present invention will be described in detail below. The present invention provides an ACE inhibitor containing one or more selected from live cells, killed cells and extracts of Lactococcus lactis N7 strain. The official name of the Lactococcus lactis N7 strain is Lactococcus lactis subsp. lactis biovar diacetylactis N7 strain, and it has been deposited at the Patent Microorganisms Depositary Center of the National Institute of Technology and Evaluation, with the accession number FERM P-18217. The lactic acid bacteria N7 strain in the present invention was selected as a strain with extremely high ACE inhibitory activity from among the strains stored in the lactic acid bacteria library held by the Livestock Products Research Division of the Livestock Research Department of the National Agriculture and Food Research Organization. Although a detailed description will be given in the Examples below, the ACE inhibitory activity of the lactic acid bacteria N7 strain in the present invention is approximately 1.7-fold higher than that of the lactic acid bacteria H61 strain, which the inventors have confirmed has the effect of suppressing the decrease in the viability of normal human epidermal keratinocytes due to ultraviolet UV-B irradiation (Non-Patent Document 3), and therefore its usefulness is considered to be extremely high.

[0012] <Culture conditions> The culture conditions for the lactic acid bacteria N7 strain of the present invention are not particularly limited, and the strain can be cultured under conventionally known conditions. Examples of the culture medium include a medium containing necessary nutrient sources such as carbon sources, nitrogen sources, or inorganic salts that can be assimilated by lactic acid bacteria belonging to the genus Lactococcus. Any natural or synthetic medium may be used as long as the medium can grow lactic acid bacteria, and a person skilled in the art can appropriately select an appropriate known medium to be used. Examples of the carbon source that can be used include glucose, lactose, galactose, fructose, trehalose, sucrose, mannose, blackstrap molasses, and the like, and examples of the nitrogen source that can be used include meat extract, peptone, yeast extract, casein hydrolysate, whey protein hydrolysate, soy protein hydrolysate, and the like. Examples of inorganic salts that can be used include phosphates, sodium, potassium, magnesium, and the like. Examples of media suitable for culturing lactic acid bacteria include, for example, M17 medium (with glucose added), MRS liquid medium, GYP medium, TYG medium, GAM medium, animal milk, skim milk, and dairy whey, and among these, MRS medium is preferred. The ACE inhibitory activity of the lactic acid bacteria N7 strain of the present invention can be improved by culturing it in MRS medium (carbon source: glucose) which is commonly used for culturing lactic acid bacteria, but substituting another sugar source. In particular, it has been confirmed in the examples described below that the ACE inhibitory activity is improved by culturing it in a medium containing added lactose and / or fructose, compared to the case where glucose is added.

[0013] The culture conditions are not particularly limited as long as they allow the growth of lactic acid bacteria. Although there are no particular limitations on the pH of the medium, it is usually in the range of pH 5 to 7, and preferably pH 6 to 7. The medium and culture device can be sterilized at a low temperature of 100° C. or less before use. The culture temperature may be set within the range of growth temperatures for the lactic acid bacteria N7 strain, preferably within the range of the optimal growth temperature, for example, 4° C. to 40° C., preferably about 25 to 30° C. The culture time is not limited, but may be, for example, about 1 to 2 days. During the cultivation, there is no need to block or supply oxygen. The cultivation method may be static cultivation, shaking cultivation, tank cultivation, or the like.

[0014] <Heat treatment> It has also been confirmed by the experimental examples described below that the ACE inhibitory activity of the lactic acid bacteria N7 strain of the present invention, which has been heat-treated after cultivation, is significantly improved compared to the ACE inhibitory activity of live bacteria. Here, the heat treatment refers to, for example, placing the water suspension of the bacterial cells in a block heater or a hot water bath and keeping it warm for a certain period of time. Suitable temperatures for the heat treatment include, but are not limited to, 95°C, 100°C, and 121°C.

[0015] The lactic acid bacteria N7 strain contained in the ACE inhibitor of the present invention may be in the form of live or killed cells, or an extract. In the present invention, the extract refers to the supernatant obtained after precipitating the bacterial cell portion suspended in a solvent such as water by centrifugation. The supernatant obtained by heating the bacterial cell suspension in water and then centrifuging the suspension is called a "hot water extract," while the supernatant obtained by suspending the bacterial cell in unheated water and centrifuging the suspension is called a "water extract." Both of these are included in the extract of the present invention. In the examples, all that is actually used are extracts, but since the substances contained in the extracts are originally contained within the bacterial cells, it is believed that both live and dead bacterial cells contain substances that have ACE inhibitory effects. It is believed that the ACE inhibitory activity of the bacterial cells is related to glycoproteins in the bacterial cells, and because the sugar components are extracted with hot water, it is believed that the amount of the components extracted will be greater than that of live bacteria.

[0016] The skin aging inhibition composition and wrinkle improving composition of the present invention can be administered as the above-mentioned bacterial cells or extract as is, or after diluting with water or the like. In addition, as a component constituting the wrinkle improving composition, other components used in skin external preparations and the like can be appropriately blended as necessary within a range that does not impair the effects of the present invention. Examples of the other components (optional blending components) include oils, surfactants, powders, coloring materials, water, alcohols, thickeners, chelating agents, silicone agents, antioxidants, ultraviolet absorbers, moisturizers, fragrances, various medicinal ingredients, preservatives, pH adjusters, neutralizers, etc. EXAMPLES

[0017] The present invention will be described below with reference to examples, but the technical scope of the present invention is not limited to these examples.

[0018] <Example 1: Confirmation test of ACE inhibitory activity of lactic acid bacteria strain N7> (1) Test specimen Lactic acid bacteria strains N7 and H61 were each cultured overnight at 30° C. in MRS medium (Becton, Dickinson and Company, Sparks, MD, USA), then centrifuged at 5000 g for 10 minutes to collect the bacteria, which were then washed twice with 0.85% sodium chloride solution, suspended in water, and heat-treated for 15 minutes at 121° C. The sample was freeze-dried to prepare freeze-dried killed bacterial powder, which is widely used in industry, and used as a test specimen for measuring ACE inhibitory activity. 2 mg of each test sample was taken and suspended in water. This water suspension of killed bacteria was centrifuged at 13,000 g for 10 minutes, and the resulting supernatant (water extract of killed bacteria) was diluted 10-fold with water and subjected to the same ACE inhibitory activity test as in Example 1. (2) Test method The ACE inhibitory activity was measured using an ACE inhibitory activity measurement kit (DOJINDO LABORATORIES, Kumamoto) according to the kit's protocol. 1. In a 96-well microplate, add 20 μL of sample to sample wells, blank 1 and blank 2 wells. 2. Add 20 μL of reaction substrate included in the kit to each well. 3. Add 20 μL of water to blank 2 well. 4. Add 20 μL of enzyme reaction solution to the sample wells and blank 1 well. 5. Place a sticker on the plate and incubate in a 37℃ incubator for 1 hour. 6. Add 200 μL of indicator solution to each well. 7. Incubate the plate at room temperature for 10 minutes. 8. Measure the absorbance at 450 nm using a microplate reader (BIO-RAD Model 3550 Microplate Reader (Hercules, CA)). [Calculation formula for ACE inhibitory activity] ACE inhibitory activity (%) = [(A blank1 -A sample ) / (A blank1 -A blank2 )] x 100 A blank1 : Water absorbance (450 nm) A blank2 : Absorbance of reaction substrate A sample : Absorbance of bacterial sample The test results are shown in Figure 1.

[0019] (3) Results 1, the ACE inhibitory activity of the lactic acid bacteria N7 strain in the present invention was 54.3%, while that of the lactic acid bacteria H61 strain was 32.8%. In other words, it was revealed that the ACE inhibitory activity of the lactic acid bacteria N7 strain was about 1.7 times higher than that of the lactic acid bacteria H61 strain. The inventors have confirmed that the lactic acid bacteria H61 strain has the effect of suppressing the decrease in the viability of normal human epidermal keratinocytes due to ultraviolet UV-B irradiation, and therefore the N7 strain is expected to have a beneficial effect against photoaging. As described above, it was confirmed that the lactic acid bacteria strain N7 of the present invention has high ACE inhibitory activity.

[0020] <Example 2: Confirmation test 1 regarding culture conditions and ACE inhibitory activity of lactic acid bacteria N7 strain> For the lactic acid bacteria N7 strain, the MRS culture medium was inoculated with 0.5% (v / v) of the MRS culture solution cultured overnight at 30 ° C. (stationary phase), 5.5 hours (logarithmic phase), and 37 ° C. overnight cultured cells were collected, washed three times with water, and suspended in water to 100 mg / mL (wet cell weight w / v). This water suspension of cells was heat-treated at 95 ° C. for 15 minutes and centrifuged at 13000 g for 10 minutes. The supernatant (hot water extract) was subjected to the ACE inhibitory activity test described in Example 1, and the ACE inhibitory activity (%) was calculated according to the ACE inhibitory activity calculation formula.

[0021] (3) Results The test results are shown in Table 1. [Table 1] The values ​​in Table 1 represent average values ​​(standard deviations). In Table 1, * indicates P<0.05 vs. control (30°C, stationary phase, heat treatment).

[0022] From the results in Table 1 above, it was found that the ACE inhibitory activity of the lactic acid bacteria N7 strain was higher at a culture temperature of 30°C than at 37°C, higher in stationary phase culture than in logarithmic phase culture, and higher in heat-treated cells than in cells that were not heat-treated. Therefore, it was revealed that the optimal culture conditions for the N7 strain are overnight culture at 30°C.

[0023] <Example 3: Confirmation test 2 regarding culture conditions and ACE inhibitory activity of lactic acid bacteria N7 strain> (1) Test method A carbohydrate (glucose)-free MRS medium (C free MRS) was prepared. This MRS medium (C free MRS) contains 1% proteose peptone, 0.5% yeast extract, 0.1% Tween 80, 0.2% ammonium citrate, 0.5% sodium acetate, 0.01% magnesium sulfate, 0.005% manganese sulfate, and 0.2% dipotassium phosphate (pH 6.5). A 10% solution of glucose, fructose, lactose, and galactose was prepared, and filtered and sterilized with a filter (0.2 μm, manufactured by Advance Co., Ltd.). This solution was added to the above MRS medium so that the final concentration was 0.5% (v / v). The N7 strain was cultured overnight in 10% skim milk, and one platinum loop of the culture was suspended in a 0.85% sodium chloride solution, and the resulting bacterial solution was inoculated into each medium at a concentration of 0.5% (v / v) and cultured overnight. The cultured bacterial cells were collected, washed three times with water, and then suspended in water to a concentration of 100 mg / mL (wet bacterial cell weight w / v). This bacterial cell water suspension was heat-treated at 95 ° C. for 15 minutes, centrifuged at 13000 g for 10 minutes, and the supernatant (hot water extract) was subjected to the ACE inhibitory activity test described in Example 1, and the ACE inhibitory activity (%) was calculated according to the ACE inhibitory activity calculation formula.

[0024] (2) Results The test results are shown in Table 2. [Table 2] The values ​​in Table 2 are shown as average values ​​(standard deviations). Different letters in Table 2 indicate significant differences (P<0.05).

[0025] The results in Table 2 above confirm that the ACE inhibitory activity of the Lactobacillus casei N7 strain varies depending on the type of carbon source in the medium, and that the ACE inhibitory activity is higher when cultured in a medium containing lactose and / or fructose than when the commonly used glucose-containing medium is used.

[0026] Example 4: Cytotoxicity of Lactobacillus casei N7 strain to normal human dermal fibroblasts (1) Test specimen Lactic acid bacteria N7 strain was cultured overnight at 30° C. in MRS medium, harvested, washed three times with water, suspended in water, and heat-treated for 15 minutes at 121° C. This water suspension of bacteria was centrifuged at 13,000 g for 10 minutes, and the supernatant (hot water extract) was collected and lyophilized to prepare the test specimen. (2) Test method Normal human dermal fibroblasts were cultured at 1.0 × 10 4 The cells were seeded in a 48-well plate at a cell density of 1000 cells / well. After 24 hours of culture, the medium was replaced with DMEM (5% FBS) containing the above-mentioned test samples at the concentrations shown in Table 3 below, and cultured for 72 hours. After culture, the cells were harvested by trypsinization, and the number of cells was counted using flow cytometry. The measured values ​​were subjected to a significant difference test using the Student-t test.

[0027] (3) Results The test results are shown in Table 3. [Table 3] In Table 3, (1) indicates a significant difference compared to untreated cells.

[0028] As shown in Table 3, at a concentration of 10 mg / mL of hot water extract of lactic acid bacteria N7 strain cells, abnormalities were observed in the morphology of normal human dermal fibroblasts and a tendency for the Index (%) to decrease was observed compared to when no sample was added. Therefore, in the following Example 5, the maximum concentration was set to 5 mg / mL. It was also revealed that the addition of 0.04 to 5 mg / mL of a hot water extract of Lactobacillus acidophilus N7 strain had no effect on the survival of normal human dermal fibroblasts.

[0029] <Example 5: Examination of the effect of lactic acid bacteria strain N7 on the cell proliferation ability of normal human dermal fibroblast senescence-induced cells> (1) Preparation of senescence-induced cells Normal human dermal fibroblasts were added with DMEM (0% FBS) containing 600 μmol / L hydrogen peroxide, which had been adjusted just before use, and cultured at 37°C for 1 hour. After culturing for 1 hour, the hydrogen peroxide-containing DMEM (0% FBS) was removed and DMEM medium (10% FBS) was added. This procedure was repeated for 4 days, and then the cells were cultured in DMEM medium (10% FBS) for 3 days. The cells obtained here were used as senescence-induced cells. Senescence of senescence-induced cells was assessed by SA-β-Gal staining. That is, senescence-induced cells and non-senescence-induced cells were cultured at 5 × 10 4 The cells were seeded in a 48-well plate at a cell density of 1000 cells / well. After 24 hours of culture, the cells were fixed in PBS containing 3% formaldehyde. The cells were then replaced with a pH 6 reaction solution (40 mmol / L citric acid / sodium phosphate, 0.5 mmol / L potassium ferrocyanide, 5 mmol / L potassium ferricyanide, 150 mmol / L sodium chloride, 2 mmol / L magnesium chloride) containing 1 mg / mL X-Gal, and cultured for 16 hours. After culturing, the researchers performed microscopic observations to compare the staining intensity of SA-β-Gal, a senescence marker, between non-senescence-induced cells and senescence-induced cells, confirming that the staining intensity was increased in the senescence-induced cells compared to the non-senescence-induced cells.

[0030] (2) Cell proliferation evaluation test Senescence-induced cells and non-senescence-induced cells were cultured at 1.0 × 10 4 The cells were seeded in a 48-well plate at a cell density of 10 ...

[0031] [Table 4] In Table 4, (1) indicates a significant difference between non-senescence-induced cells and untreated cells. In Table 4, (2) indicates a significant difference between senescence-induced cells and untreated cells.

[0032] (3) Results As shown in Table 4, the cell number of senescence-induced cells was significantly decreased compared to non-senescence-induced cells. It was confirmed that when a hot water extract of Lactobacillus casei N7 strain cells was added in the range of 0.5 to 5.0 mg / mL to senescence-induced normal human dermal fibroblast cells, the cell number was significantly increased compared to when no extract was added, and the cell proliferation ability was increased. [Industrial Applicability]

[0033] According to the present invention, it is possible to provide a highly safe ACE inhibitor derived from Lactococcus lactic acid bacteria, and also to provide a skin aging inhibition composition and a wrinkle improving composition using the same.

Claims

1. An angiotensin-converting enzyme inhibitor comprising at least one substance selected from live cells, killed cells and extracts of Lactococcus lactis N7 strain (deposit number: FERM P-18217).

2. A composition for inhibiting skin aging, comprising the angiotensin converting enzyme inhibitor according to claim 1 as an active ingredient.

3. A wrinkle-improving composition comprising the angiotensin-converting enzyme inhibitor according to claim 1 as an active ingredient.

4. A method for increasing angiotensin-converting enzyme inhibitory activity, comprising culturing Lactococcus lactis N7 strain (deposit number: FERM P-18217) in the presence of one or more carbon sources selected from glucose, fructose, galactose and lactose and / or heat treating the strain.

Images